Lise Ripken
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lise Ripken has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Cornelia Rosanne Maria Ausems
Department of Human Genetics, Radboud University Medical Center, Donders lnstitute for Brain Cognition and Behavior, 6525 GA Nijmegen, the Netherlands
1 shared publication - Derick Gert Wansink
Radboud University Medical Center
1 shared publication - Renée Henrica Lamberta Raaijmakers
Radboud University Medical Center, Radboud Institute for Medical Innovation and Donders Institute for Brain Cognition and Behaviour, Department of Human Genetics, 6500 HB Nijmegen, the Netherlands; Radboud University Medical Center, Radboud Institute for Medical Innovation, Department of Medical BioSciences, 6525 GA Nijmegen, the Netherlands
1 shared publication
Latest Publications
- Open Access
- 27 July 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (15) , 3689
CRISPR/Cas Applications in Myotonic Dystrophy: Expanding Opportunities
CRISPR/Cas technology holds promise for the development of therapies to treat inherited diseases. Myotonic dystrophy type 1 (DM1) is a severe neuromuscular disorder with a variable multisystemic character for which no cure is yet available. Here, we review CRISPR/Cas-mediated approaches that target the unstable (CTG•CAG)n repeat in the DMPK/DM1-AS gene pair, the autosomal dominant mutation that causes DM1. Expansion of the repeat results in a complex constellation of toxicity at the DNA level, an altered transcriptome and a disturbed proteome. To restore cellular homeostasis and ameliorate DM1 disease symptoms, CRISPR/Cas approaches were directed at the causative mutation in the DNA and the RNA. Specifically, the triplet repeat has been excised from the genome by several laboratories via dual CRISPR/Cas9 cleavage, while one group prevented transcription of the (CTG)n repeat through homology-directed insertion of a polyadenylation signal in DMPK. Independently, catalytically deficient Cas9 (dCas9) was recruited to the (CTG)n repeat to block progression of RNA polymerase II and a dCas9-RNase fusion was shown to degrade expanded (CUG)n RNA. We compare these promising developments in DM1 with those in other microsatellite instability diseases. Finally, we look at hurdles that must be taken to make CRISPR/Cas-mediated editing a therapeutic reality in patients.
- 27 July 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (15) , 3689
Open AccessCRISPR/Cas Applications in Myotonic Dystrophy: Expanding Opportunities
CRISPR/Cas technology holds promise for the development of therapies to treat inherited diseases. Myotonic dystrophy type 1 (DM1) is a severe neuromuscular disorder with a variable multisystemic character for which no cure is yet available. Here, we review CRISPR/Cas-mediated approaches that target the unstable (CTG•CAG)n repeat in the DMPK/DM1-AS gene pair, the autosomal dominant mutation that causes DM1. Expansion of the repeat results in a complex constellation of toxicity at the DNA level, an altered transcriptome and a disturbed proteome. To restore cellular homeostasis and ameliorate DM1 disease symptoms, CRISPR/Cas approaches were directed at the causative mutation in the DNA and the RNA. Specifically, the triplet repeat has been excised from the genome by several laboratories via dual CRISPR/Cas9 cleavage, while one group prevented transcription of the (CTG)n repeat through homology-directed insertion of a polyadenylation signal in DMPK. Independently, catalytically deficient Cas9 (dCas9) was recruited to the (CTG)n repeat to block progression of RNA polymerase II and a dCas9-RNase fusion was shown to degrade expanded (CUG)n RNA. We compare these promising developments in DM1 with those in other microsatellite instability diseases. Finally, we look at hurdles that must be taken to make CRISPR/Cas-mediated editing a therapeutic reality in patients.